Humacyte (HUMA) vs Innate Pharma S.A. (IPHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Innate Pharma S.A. (IPHA) has outperformed Humacyte (HUMA) over the past year, losing 26.4% versus a loss of 73.5%. Over five years, IPHA leads with a -74.8% price change compared with -95.6% for HUMA. Innate Pharma S.A. is the larger company by market cap ($172.0 million vs $118.9 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUMA | IPHA |
|---|---|---|
| Share price | $0.428 | $1.54 |
| Market cap | $118.90M | $172.02M |
| 1-day change | -4.27% | +4.05% |
| YTD return | -53.48% | -15.43% |
| 1-year return | -73.54% | -26.37% |
| 5-year return | -95.63% | -74.79% |
| EPS (TTM) | $-0.51 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.90 | $2.71 |
| 52-week low | $0.4254 | $1.17 |
| Distance from 52-week high | -77.41% | -43.17% |
| Analyst consensus | buy | none |
| Avg. price target upside | +280.84% | +333.12% |
| Average volume | 6.23M | 156.96K |
| Shares outstanding | 277.80M | 111.70M |
| Employees | 184 | 120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPHA has outperformed HUMA by 47.2 percentage points over the past year.
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 184 employees
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees
HUMA vs IPHA FAQ
Which is bigger, Humacyte or Innate Pharma S.A.?
Innate Pharma S.A. (IPHA) is larger, with a market capitalization of $172.02M compared with $118.90M for Humacyte (HUMA).
Which stock has performed better over the past year, HUMA or IPHA?
IPHA returned -26.37% over the past 12 months, compared with -73.54% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Humacyte and Innate Pharma S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.